Fox Chase Cancer Center Named A Center of Excellence
PHILADELPHIA (November 19, 1999) -- Fox Chase Cancer Center has been named a Center of Excellence by Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP). Now, Fox Chase has a new way to form mutually beneficial relationships with Pennsylvania's technology-based companies by offering its Center for Biotech and Biostatistical Services.
Fox Chase Cancer Center has a long history of partnering with companies ranging from large pharmaceuticals to young biotech companies. Through participation in the Centers of Excellence Service Network, Fox Chase will provide reasonable-cost, quality research support services to small and medium-sized biotechnology companies in southeastern Pennsylvania as well as throughout the state. Subsidization from BFTP will allow Fox Chase to offer low-cost service to companies through this program.
As a major research institution, Fox Chase Cancer Center maintains sophisticated research services and specialized facilities, whose purpose is to provide critical support to Fox Chase investigators. As a member of the Centers of Excellence Service Network, Fox Chase's Center for Biotech and Biostatistical Services will offer the following resources: the DNA Sequencing Facility, the Fannie E. Rippel Biotech Facility, the Histopathology Facility, the Organic Synthesis Laboratory and the Biostatistical Consulting Service.
Small biotechnology companies, especially start-ups, often find themselves needing to outsource many of their research support functions due to limited internal resources. The Center for Biotech and Biostatistical Services can provide many of these functions that can aid company growth in a cost-effective manner. Benefits to companies include savings on expensive laboratory space, equipment and personnel; the opportunity to interact with Fox Chase's world class scientists and clinicians; and the ability to capitalize upon the experience of other similar projects performed at Fox Chase.
"This is a win-win situation," said Patricia Harsche, Vice President, Business Development & Regulatory Affairs, Fox Chase. "While biotechnology companies will have the tools to expand and contribute to the Pennsylvania economy, Fox Chase will be planting the seeds for future partnerships with these area companies as they grow and mature."
Ben Franklin Technology Partners of Southeastern Pennsylvania, a part of a statewide network, is an independent, nonprofit economic development corporation whose mission is to promote economic competitiveness in the five-county region through innovation and technology. In achieving this mission, Ben Franklin forms strategic partnerships with economic development organizations, research institutions and universities to provide financing and technology solutions for technology-based and growth-oriented companies.
Fox Chase Cancer Center is one of 37 National Cancer Institute-designated comprehensive cancer centers in the nation. The Center's activities include basic and clinical research; prevention, detection and treatment of cancer; and community outreach programs.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Diana Quattrone at 215-728-7784.